ADORA2B (Adenosine A2b Receptor) encodes a G protein-coupled receptor that plays important roles in modulating cellular responses to adenosine. While less studied than its sibling receptor ADORA2A, ADORA2B has emerged as an important player in neuroinflammation, hypoxia response, and increasingly recognized in neurodegenerative disease processes.
| Property |
Value |
| Gene Symbol |
ADORA2B |
| Gene Name |
Adenosine A2b Receptor |
| Chromosomal Location |
17p12 |
| NCBI Gene ID |
136 |
| OMIM |
600446 |
| UniProt |
P29274 |
| Ensembl |
ENSG00000171490 |
| Protein Class |
G protein-coupled receptor, rhodopsin family |
ADORA2B is one of four adenosine receptor subtypes (A1, A2A, A2B, A3) belonging to the G protein-coupled receptor superfamily:
- Gαs-coupled — Stimulates adenylate cyclase, increasing cAMP levels
- Low Affinity — Requires higher adenosine concentrations than A2A receptor (Kd ~10-20 μM vs ~0.5-5 μM for A2A)
- Hypoxia-Inducible — Expression increases under hypoxic conditions via HIF-1α response elements
- Pro-inflammatory — Activation generally promotes inflammatory responses through cAMP/PKA signaling
Upon adenosine binding, ADORA2B activates the following signaling cascades:
- cAMP/PKA Pathway — Gαs stimulates adenylate cyclase → increased cAMP → PKA activation → CREB phosphorylation
- PI3K/Akt Pathway — β-arrestin recruitment activates PI3K → Akt phosphorylation → cell survival signals
- MAPK Pathway — ERK1/2 activation through both cAMP-dependent and β-arrestin-dependent mechanisms
- NF-κB Pathway — cAMP can either inhibit or promote NF-κB depending on cell type and context
- Brain — Expressed in astrocytes, microglia, neurons, and endothelial cells of the blood-brain barrier
- Peripheral — High expression in lung, bladder, testis, and immune cells (macrophages, dendritic cells)
- Induction — Strongly upregulated during inflammation and hypoxia; expression is tissue-specific and dynamically regulated
ADORA2B shares the typical 7-transmembrane domain structure of Class A GPCRs:
- Extracellular N-terminus — Short, involved in ligand recognition
- Transmembrane domains — Seven α-helices (TM1-TM7) forming the orthosteric binding pocket
- Intracellular loops — ICL2 and ICL3 interact with G proteins and β-arrestins
- C-terminal tail — Contains serine/threonine residues for phosphorylation and β-arrestin binding
The ligand-binding pocket is larger and more hydrophilic than A2A receptor, accommodating the lower-affinity adenosine analog binding.
ADORA2B plays complex roles in neuroinflammation:
- Glial Activation — Regulates microglial and astrocyte inflammatory responses through cAMP-dependent pathways
- Cytokine Production — Modulates production of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and anti-inflammatory cytokines (IL-10)
- Blood-Brain Barrier — Affects BBB permeability and leukocyte transmigration into the CNS
- NLRP3 Inflammasome — A2B receptor activation can inhibit NLRP3 inflammasome assembly in some contexts
ADORA2B has emerging roles in AD pathophysiology:
- Amyloid Response — ADORA2B modulates inflammatory responses to amyloid-beta accumulation
- Autophagy — A2B receptor activation facilitates autophagic clearance of Aβ through mTOR-independent pathways
- Cognitive Function — A2B receptor activation affects memory and cognition through hippocampal signaling
- Therapeutic Target — A2B antagonists being explored for AD treatment, though brain penetration remains a challenge
- tau Pathology — Limited evidence for direct A2B-tau interactions but neuroinflammation modulation may affect tau propagation
In PD models, ADORA2B signaling shows protective potential:
- Dopaminergic Protection — A2B receptor activation may protect dopaminergic neurons from 6-OHDA and MPTP toxicity
- Neuroinflammation — Modulates microglial responses and reduces neurotoxic cytokine production
- α-Synuclein — May influence α-synuclein aggregation through autophagy regulation
- Therapeutic Consideration — A2B agonists vs antagonists remains debated; timing and disease stage likely critical
¶ Stroke and Brain Injury
- Hypoxia Response — ADORA2B is strongly upregulated during ischemic events via HIF-1α
- Neuroprotection — A2B activation can be protective in stroke models through angiogenesis and anti-inflammatory effects
- Blood-Brain Barrier — Protects BBB integrity during ischemic injury
- Autoimmune Modulation — A2B signaling affects T-cell migration and polarization
- Demyelination — May influence oligodendrocyte precursor differentiation
ADORA2B is a therapeutic target with ongoing drug development:
- Antagonists — PSB1115, ATL-852e; being developed for inflammatory conditions, asthma, and diabetic complications
- Agonists — BAY60-6583, NPS568; explored for stroke, ischemic protection, and heart failure
- Brain Penetration — Significant challenge in targeting CNS A2B receptors due to P-glycoprotein efflux
- Selective vs Non-selective — A2B-selective compounds vs dual A2A/A2B targeting remains under investigation
Currently no major clinical trials specifically targeting ADORA2B in neurodegeneration. A2B agonists have been studied in:
- Acute ischemic stroke (Phase I/II)
- Diabetes and metabolic syndrome
- Inflammatory conditions
- ADORA2B expression may serve as a marker of inflammatory states
- CSF ADORA2B levels could indicate neuroinflammation in neurodegenerative diseases
- Peripheral blood monocyte ADORA2B as potential biomarker under investigation
- ADORA2B Knockout Mice — Global KO mice viable with altered inflammatory responses
- Conditional Knockouts — Brain-specific and cell-type-specific Cre lines available
- Humanized Models — Transgenic mice expressing human ADORA2B for drug testing
- Agonists — BAY60-6583, MRS5841, NPS568
- Antagonists — PSB1115, ATL-852e, MRS1754
- Radioligands — [3H]PSB-1115 for binding studies